SBIA | TOMORROW - Electronic Drug Registration and Listing (eDRLS) Using CDER Direct Workshop

Don't miss out!

Receive this email as a forward? Subscribe to CDER SBIA industry updates. FDA | CDER | Small Business and Industry Assistance CONFERENCE Electronic Drug Registration and Listing (eDRLS) Using CDER Direct TOMORROW: OCTOBER 13, 2021 | 8:45 AM - 4:00 PM ET This conference is free. Register   Agenda KEYNOTE SPEAKER Paul Loebach Branch Chief Drug Registration and Listing Branch Division of Labeling, Registration and Unapproved Drugs Office of Unapproved Drugs and Labeling Compliance Office of Compliance | CDER ABOUT This conference is part of the SBIA Regulatory Education for Industry (REdI) series and is intended to provide basic instruction in the registration and listing policy and process for those who are new to this regulatory program as well as offer regulatory professionals more in-depth information on issues and current events affecting Drug Registration and Listing. TOPICS COVERED Registration and Listing 101: FDA will demonstrate using CDER Direct how to create and submit: Establishment Registration and De-Registration Labeler Code Request and Update OTC and Rx Product Listing and Update NDC Reservation 503B Compounder Registration and Product Report FDA will discuss: the structure, use, and future of the National Drug Code (NDC) number common errors and issues encountered with submissions FDA will provide an overview of: the compliance program and process and steps a registrant should take if they receive a deficiency letter. the Over-The-Counter Monograph User Fee Program (OMUFA) and how registration is used to calculate fees. AUDIENCE Regulatory affairs professionals working on Registration and Listing or who submit structured product labeling (SPL) to FDA Members of pharmaceutical industry who submit Registration and Listing Human drug compounding outsourcing facilities U.S. Agents for foreign registrants Importers and import agents Consultants and law firms representing pharmaceutical companies CONTINUING EDUCATION Real-time attendance is required for the certificate of attendance which can be used in support of CEs for the following professional organizations.  Certificates are only available during the two weeks post-event. This course has been: pre-approved by RAPS as eligible for a maximum of 12 credits for a two day event (appropriate to real-time attendance) towards a participant's RAC recertification upon full completion. pre-approved by SOCRA who accepts documentation of candidate participation in continuing education programs for re-certification if the program is applicable to clinical research regulations, operations or management, or to the candidate's clinical research therapeutic area. pre-approved by SQA as eligible for 1 non-GCP or non-GLP unit for every 1 hour of instructional time towards a participant's RQAP re-registration. approved by ACRP for continuing education in clinical research. ACRP will provide 1 ACRP contact hour for every 45-60 minutes of qualified material. The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research provides guidance, education and updates for regulated industry. Register for Upcoming Training Watch Learning Library Recordings on YouTube Subscribe to CDER SBIA Email Updates Follow on LinkedIn Follow on Twitter

This is an automated message delivery system. Replying to this message will not reach the CDER SBIA staff. If you have comments or questions, contact us at CDERSBIA@fda.hhs.gov or 1-866-405-5367 or (301) 796-6707.   SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA